Tag

MAbs

Panel: Reflecting on the Past and Shaping the Future: Enhancing Our Influence on Medicine
LIFE SCIENCES, VIDEO, LIFE SCIENCES

Panel: Reflecting on the Past and Shaping the Future: Enhancing Our Influence on Medicine

May 29, 2025

Evaluating which production platforms will be most effective for emerging modalities, such as rAAV gene therapies
Considering the next steps for established platforms like mAbs, ADCs, and mRNA: How can we efficiently address significant markets, such as treatments for Alzheimer’s
Examining the changes within the CMC ecosystem and assessing whether we are once again overextending our capacity
Addressing the risks of fragmentation: How can we improve communication, collaboration, and the consolidation of our best ideas to ensure collective success?
Discussing the motivations for launching new companies today and envisioning the future growth and evolution of our business ecosystem

Continue reading
Panel Discussion: Reflecting on the Past, Envisioning the Future: Shaping the New Landscape of Biomanufacturing
LIFE SCIENCES, VIDEO, LIFE SCIENCES

Panel Discussion: Reflecting on the Past, Envisioning the Future: Shaping the New Landscape of Biomanufacturing

December 2, 2024

Assessing Changes in the CMC Ecosystem: Are We Overbuilding Capacity Again?
Uniting for Success: Strategies to Prevent Fragmentation and Foster Collaboration in Biomanufacturing
Pioneering New Ventures: Reasons to Establish a New Company Today and Anticipating Future Growth in the Business Ecosystem
Evaluating Production Platforms for Emerging Modalities: Which Platforms Will Best Serve the Future of Medicine?
Navigating the Future of Existing Platforms: Efficiently Addressing Market Needs for Established Therapies such as mAbs, ADCs, and mRNA-based Treatments

Continue reading
COVID-19 MAbs at Pandemic Speed, Volumes and COGs
LIFE SCIENCES, VIDEO, LIFE SCIENCES

COVID-19 MAbs at Pandemic Speed, Volumes and COGs

December 1, 2020

Vir Biotech has discovered a neutralizing COVID-19 mAb to a unique, highly conserved Coronavirus spike sequence, high barrier to resistance and effector function We have partnered with numerous CDMOs and GSK to move from discovery to the clinic in approximately 6 months World-wide pandemic requirements for an efficacious neutralizing mAb may exceed 20 metric tons – challenging the capacity of industry manufacturing infrastructure — Michael Kamarck Chief Technology Officer Vir Biotechnology Michael Kamarck is Chief Technology Officer at Vir. Previously, he was senior vice president of Global Vaccines and Biologics Manufacturing and president of Merck BioVentures where he was responsible…

Continue reading

  • NASCES

  • NAFS

  • NAFMS

  • EUSCES

  • BMWS

  • NALES

  • MDMES

  • NAFES

  • NASRS

  • NAHRES

  • NAMES

  • PMWS

  • NAISS